In a multi-cohort study, previously treated, advanced HCC patients treated with combination therapy of PD-L1 inhibitor Durvalumab and anti-VEGFR2 antibody Ramucirumab, the high PD-L1 subgroup showed longer OS and PFS, compared with low PD-L1 subgroup (11). This evidence concerns the gene CD274 and hepatocellular carcinoma.